Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2017

View Archived Issues

PharmaMar starts phase I study of PM-14 in solid tumors

IPH-5401 development transitions from arthritis to immuno-oncology

Novel OTC gene mutation tied to intermittent hyperammonemia

FDA approves BioCryst's Rapivab in pediatric patients

Paratek's omadacycline awarded third FDA QIDP designation

Novel PI4KII-BETA inhibitors discovered at Stanford, UC Oakland

ATB-200/AT-2221 receives U.S. orphan drug status for Pompe disease

Bill & Melinda Gates Foundation, Anacor present boron-containing pleuromutilins

Bayer discovers new BUB1 inhibitors

Otsuka divulges novel compounds for brain cancer

MUT gene mutation linked to methylmalonic aciduria

Great apes adenovirus multiantigenic vaccine enhances anti-PD1 therapy in vivo

Disarm Therapeutics announces USD 30 million series A financing

Abivax receives French regulatory approval to begin phase IIa study of ABX-464 in ulcerative colitis

FDA grants rare pediatric disease designation to Altemia for SCD in children

DxTerity collaborates with City of Hope on blood test to predict response to radiation therapy

Phase III trial of somavaratan in pediatric growth hormone deficiency does not meet primary endpoint

Cellectar Biosciences, Onconova Therapeutics to jointly develop phospholipid drug conjugates

Phase IIb study of EMI-137 begins

Karyopharm reports first-in-human data for KPT-9274

Soligenix receives funding to support phase III study of SGX-972

Provention Bio in-licenses two clinical-stage assets from Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...